Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Former Pfizer CEO Kindler Named To Presidential Board On Government "Best Practices"

This article was originally published in The Pink Sheet Daily

Executive Summary

Jeffrey Kindler will bring the big pharma perspective to the newly-constituted President's Management Advisory Board.

You may also be interested in...



People In The News: Tracking The Latest Industry Personnel Moves

Don Berwick steps down as CMS chief; new leadership at BIO Ventures for Global Health; former Pfizer CEO Kindler joins two boards of directors; more personnel announcements in this month’s column.

Pfizer Turns To Insider Ian Read To See It Into Post-Lipitor Era

The 32-year Pfizer veteran will take over for Jeffrey Kindler in a succession viewed as a surprise by Wall Street.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071943

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel